Alliqua completes transdermal discomfort patch initial study for treatment of PHN Alliqua.

Alliqua completes transdermal discomfort patch initial study for treatment of PHN Alliqua, Inc., an advanced biomedical products company centered on the development and production of proprietary drug liver and delivery wellness technologies, announced today the successful completion of its initial study for the transdermal pain patch project http://tadalafilo.org . In the comparative dissolution study, the Alliqua patch demonstrated a good profile in comparison with the market leading product for treatment of PHN discomfort. Administration estimates that global value of the PHN pain patch marketplace today is around US$1.4 billion.